SpeeDx tests go beyond simple detection, providing clinically relevant information to support patient management and inform treatment decisions.
Antibiotic resistance in sexually transmitted infections (STIs) is a growing public health issue due to the misuse and overuse of antibiotics. STIs have the potential to become the first incurable bacterial infections since the introduction of antibiotics. Diagnostic tests that detect bacterial infection and genetic markers for antibiotic resistance in a single test can address this looming issue by enabling Resistance Guided Therapy.
Thousands of people suffer from flu like symptoms each year. Diagnostic tests need to easily detect and differentiate between key respiratory viruses, for effective management of vulnerable patients in a timely manner. Our respiratory range combines clinically relevant respiratory pathogen targets into a single, rapid, test solution to simplify laboratory testing, reduce result turn around time, and improve patient management.
Improve productivity and streamline laboratory workflow with SpeeDx automation solutions. Flexible operation and programming for sample extraction preparation and/or qPCR reaction set-up. Compact, easy-to-use, and affordable solution to minimise hands-on-time and reduce overall turn-around-time.
Confirming or re-extracting samples due to an unexpected result can be time consuming and delay reporting. SpeeDx provides controls and auxiliary products cover your quality and process requirements while simplifying and streamlining your workflow.
Continued collaboration with research institutes, clinical researchers and university laboratories enables us to provide the tools needed to realise research ambitions, with the hope of translating your bench top discoveries into viable diagnostic tools for clinical environments.
“SpeeDx is uniquely positioned in the sexual health diagnostics space, with technology and tests that can inform treatment decisions. We are excited about the impact they are having now, in Europe and Australian markets, and we look forward to what we can achieve together with the current investors as we look to expand the offered test menu and prepare for the U.S. launch.”